An observational study in Subarachnoid Aneurysm Hemorrhage and Cerebral Vasospasm After Subarachnoid Hemorrhage, sponsored by Region Stockholm. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.
Sponsored by Region Stockholm · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Subarachnoid Hemorrhage with a site in Sweden — 3 open to participants now, 4 under way, none of them phase 3. Subarachnoid Hemorrhage · Sweden.
Among the 10 studies in Subarachnoid Hemorrhage with a site in Sweden, this one is one of 2 that started in 2025, is one of 4 observational ones, and was the 10th registered.
513 studies on the registry are indexed under Subarachnoid Hemorrhage; 131 are open to participants now.
Browse Subarachnoid Hemorrhage studies →3 of the 10 studies in Subarachnoid Hemorrhage with a site in Sweden are open now. Recruiting first, the newest first:
Turku University Hospital · Sites in Sweden, Finland
Ages 18+
Umeå University · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 92 Subarachnoid Hemorrhage studies recruiting now, 58 (63%) set no upper age limit and 5 (5%) stop at 75 or younger; 8 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 120 across 227 observational studies indexed under Subarachnoid Hemorrhage.
Median enrollment 285 across the 6 interventional studies, 700 across the 4 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 8 most frequent:
Region Stockholm is the lead sponsor of 122 studies on the registry; 70 are open to participants now.
Region Stockholm has 1 study filed under Subarachnoid Hemorrhage — fewer than ten, so there is no comparison to draw.
1 of the studies in Subarachnoid Hemorrhage with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06033378Umeå UniversityBlood Pressure Treatment in ICU Patients with Subarachniodal Haemorrhage. | 2027-09-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Subarachnoid Hemorrhage with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An observational study of patients with emerging or established severe cerebral vasospasm after subarachnoid haemorrhage, employing multimodal neuromonitoring.
Patients treated for subarachnoid haemorrhage at the Intensive care unit at Karolinska University Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Induced hypertension with norepinephrine · Drug: Endoluminal Spasmolysis
Induced hypertension with norepinephrine and/or dobutamine to attain clinically established goals of cerebral perfusion pressure in a stepwise fashion, according to clinical routine.
Endoluminal spasmolysis of cerebral arteries using i.a. Nimodipine, according to clinical protocol and neurointerventionist discretion.
Mean Flow Velocity (MFV)
Increase or decrease of Mean Flow Velocity of the medial cerebral artery as determined by Transcranial Doppler.
Time frame: Up to 12 hours post intervention
Duration of MFV change after Endoluminal Spasmolysis
Time until Mean Flow Velocity, as determined by Transcranial Doppler, returns to or surpasses baseline.
Time frame: Up to 12 hours
Associations between Mean Flow Velocity and multimodal neurophysiologic measurement variables after endoluminal spasmolysis or induced hypertension.
Associations between Mean Flow Velocities, as determined by Transcranial Doppler, and other neurophysiologic measurement variables, such as pbtO2 (partial pressure brain tissue oxygenation), SbtO2 (brain tissue saturation), qEEG (quantitative EEG), microdialysis parameters, Prx (pressure reactivity index), as well as other physiologic output parameters such as cardiac output, (as determined by left ventricular output or effective pulmonary blood flow (EPBF)).
Time frame: Up to 12 hours
Associations between Mean Flow Velocity and neuroradiological outcome after induced hypertension or endoluminal spasmolysis.
Associations between Mean Flow Velocity, as determined by Transcranial Doppler, and neuroradiologic outcome parameters such as cerebral artery diameter, perfusion parameters, mean transit time (MTT), ischemic burden.
Time frame: Up to 12 hours
Plan to share: No — Observational, hypothesis-generating study.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2029, 48 months after the start.
Of 117 non-industry observational studies under Subarachnoid Hemorrhage, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 127. This study's planned 48 months is above that.
Counting every sponsor, half of 120 studies reached it within 40 months; a quarter within 19 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.